Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple sclerosis: some possible therapeutic opportunities

C D Dijkstra1, C H Polman, F Berkenbosch

  • 1Department of Neurology, Vrije Universiteit, Amsterdam, The Netherlands.

Trends in Pharmacological Sciences
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

AJNR. American journal of neuroradiology·2016
Same author

Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.

AJNR. American journal of neuroradiology·2015
Same author

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same author

Detecting clinically-relevant changes in progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same author

The helminth Trichuris suis suppresses TLR4-induced inflammatory responses in human macrophages.

Genes and immunity·2014
Same author

Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2014
Same journal

Targeting developmental reprogramming: hPSC insights for cancer interception.

Trends in pharmacological sciences·2026
Same journal

July 2026 issue first authors.

Trends in pharmacological sciences·2026
Same journal

Chronobiomaterials for circadian-aligned brain therapeutics.

Trends in pharmacological sciences·2026
Same journal

Biosensors for translatable GPCR bias.

Trends in pharmacological sciences·2026
Same journal

ECM stiffness and epigenetics in organ fibrosis.

Trends in pharmacological sciences·2026
Same journal

Which HTT transcript to lower?

Trends in pharmacological sciences·2026
See all related articles

This review discusses new therapeutic strategies for multiple sclerosis (MS), a demyelinating disease. Targeting neuroendocrine factors like prolactin and glucocorticoids shows promise in reducing MS symptoms.

Area of Science:

  • Neuroimmunology
  • Endocrinology

Background:

  • Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system.
  • Immune system dysregulation involving T lymphocytes and macrophages underlies MS pathogenesis.
  • Experimental models of allergic encephalomyelitis mimic MS pathology and offer insights.

Purpose of the Study:

  • To review potential therapeutic interventions for MS.
  • To explore the role of neuroendocrine regulation in MS.
  • To highlight novel treatment possibilities based on recent immunological and endocrinological findings.

Main Methods:

  • Review of recent literature on MS, experimental allergic encephalomyelitis, and neuroimmunology.
  • Analysis of data on immune system regulation by neuroendocrine factors.

Related Experiment Videos

  • Discussion of therapeutic strategies targeting prolactin and glucocorticoids.

    • Main Results:

    • New models of experimental allergic encephalomyelitis provide insights into MS.
    • Autoregulatory mechanisms within the immune system suggest therapeutic targets.
    • Interference with prolactin and glucocorticoid secretion reduces MS manifestations in models.

    Conclusions:

    • Neuroendocrine control offers promising therapeutic avenues for MS.
    • Modulating prolactin and glucocorticoids may alleviate clinical and pathological features of MS.
    • Further research into these neuroimmunological interactions is warranted for MS treatment.